AirSculpt Technologies (NASDAQ:AIRS) versus Guardian Pharmacy Services (NYSE:GRDN) Head to Head Comparison

AirSculpt Technologies (NASDAQ:AIRS) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Profitability

This table compares AirSculpt Technologies and Guardian Pharmacy Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.79%	-5.83%	-2.88%
Guardian Pharmacy Services	4.50%	29.97%	16.18%

Insider and Institutional Ownership

91.5% of AirSculpt Technologies shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

AirSculpt Technologies has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Guardian Pharmacy Services has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AirSculpt Technologies and Guardian Pharmacy Services, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1	1	0	0	1.50
Guardian Pharmacy Services	0	1	9	0	2.90

AirSculpt Technologies currently has a consensus price target of $4.50, suggesting a potential upside of 171.90%. Guardian Pharmacy Services has a consensus price target of $45.57, suggesting a potential upside of 9.25%. Given AirSculpt Technologies’ higher probable upside, equities analysts clearly believe AirSculpt Technologies is more favorable than Guardian Pharmacy Services.

Earnings & Valuation

This table compares AirSculpt Technologies and Guardian Pharmacy Services”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82 million	0.79	-$11.67 million	($0.18)	-9.19
Guardian Pharmacy Services	$1.45 billion	1.43	$49.22 million	$1.03	40.50

Guardian Pharmacy Services has higher revenue and earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Summary

Guardian Pharmacy Services beats AirSculpt Technologies on 10 of the 14 factors compared between the two stocks.

About AirSculpt Technologies

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.